Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/12420
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSantiyanon N.
dc.contributor.authorYeephu S.
dc.date.accessioned2021-04-05T03:03:17Z-
dc.date.available2021-04-05T03:03:17Z-
dc.date.issued2019
dc.identifier.issn18785409
dc.identifier.other2-s2.0-85061640112
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/12420-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85061640112&doi=10.1016%2fj.jccase.2019.01.002&partnerID=40&md5=6a7366da4ac499d8657b5effd013806b
dc.description.abstractThis report explains the potential interaction between warfarin and astaxanthin in a 69-year-old Thai woman with history of ischemic stroke. Before taking astaxanthin, the patient used constant doses of warfarin, atenolol, digoxin, aspirin, omeprazole, and simvastatin concomitantly for 17 days without any signs and symptoms of adverse events. One day after astaxanthin was supplemented to her treatment regimen, ecchymosis was found on the right side of her groin and thigh. On the next day, area of ecchymosis was larger. International normalized ratio (INR) values increased from 1.4 to 10.38. Warfarin and astaxanthin were withheld and vitamin K was given. Two days later, INR reduced to 1.43 and symptoms of ecchymosis were better. Causality assessment of adverse drug reaction indicated a probable relationship between bleeding symptoms and astaxanthin supplementation. Counseling the patients and caregivers as well as monitoring for potential interactions with dietary supplements should be considered as an active process in order to prevent negative outcomes to patients undergoing warfarin therapy. <Learning objective: Astaxanthin, a powerful antioxidant, has been claimed to have benefits on the cardiovascular system. The populations with high risk of atherosclerotic diseases, including patients treated with warfarin may take astaxanthin for improving their disease and overall health status. Interestingly, warfarin displays clinically significant interactions with various dietary supplements and may have potential to develop unwanted anticoagulation effects when used concomitantly with astaxanthin.> © 2019 Japanese College of Cardiology
dc.subjectacetylsalicylic acid
dc.subjectamiodarone
dc.subjectamlodipine
dc.subjectastaxanthin
dc.subjectatenolol
dc.subjectdigoxin
dc.subjectomeprazole
dc.subjectsimvastatin
dc.subjectvitamin K group
dc.subjectwarfarin
dc.subjectactivated partial thromboplastin time
dc.subjectadult
dc.subjectarm ecchymosis
dc.subjectArticle
dc.subjectbedtime dosage
dc.subjectbrain ischemia
dc.subjectcase report
dc.subjectclinical article
dc.subjectdrug dose reduction
dc.subjectdrug potentiation
dc.subjectdysarthria
dc.subjectecchymosis
dc.subjectelectrocardiography
dc.subjectessential hypertension
dc.subjectevening dosage
dc.subjectfemale
dc.subjecthemiparesis
dc.subjecthuman
dc.subjectinguinal region ecchymosis
dc.subjectinternational normalized ratio
dc.subjectmicrocapsule
dc.subjectmiddle aged
dc.subjectmorning dosage
dc.subjectpersistent atrial fibrillation
dc.subjectpriority journal
dc.subjectrange of motion
dc.subjectswelling
dc.subjectthigh ecchymosis
dc.titleInteraction between warfarin and astaxanthin: A case report
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationJournal of Cardiology Cases. Vol 19, No.5 (2019), p.173-175
dc.identifier.doi10.1016/j.jccase.2019.01.002
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.